{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-24-000016","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2024-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.926643+00:00","generated_at":"2026-06-03T06:27:34.786590+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AbbVie Q1 adjusted EPS $2.31 (-6.1% YoY); raises 2024 guidance; CEO succession","bullets":["Q1 revenue $12.31B (+0.7% reported, +1.6% operational); GAAP EPS $0.77, adjusted EPS $2.31.","Immunology revenue $5.371B (-3.9%) on Humira erosion; Skyrizi +47.6%, Rinvoq +59.3%.","Oncology +9% to $1.543B; Neuroscience +15.9% to $1.965B; Aesthetics -4% to $1.249B.","Raises 2024 adjusted EPS guidance to $11.13-$11.33 from $10.97-$11.17; includes $0.08 IPR&D impact.","CEO succession: Robert Michael to become CEO July 1; Richard Gonzalez becomes executive chairman."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-24-000016","json":"https://secwatch.observer/filing/0001551152-24-000016.json","markdown":"https://secwatch.observer/filing/0001551152-24-000016.md","text":"https://secwatch.observer/filing/0001551152-24-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000016/0001551152-24-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000016/abbv-20240426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T06:27:34.786590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a15e0ed6652befab7bc4f52d528d1b90b9ffb54c","claim":"AbbVie Inc. reported the first quarter ended March 31, 2024 results: revenue $12.310 Billion, EPS Diluted EPS of $0.77 on a GAAP Basis. Guidance raised.","evidence_excerpt":"Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and Milestones Expense • Delivers First-Quarter Net Revenues of $12.310 Billion, an Increase of 0.7 Percent on a Reported Basis and 1.6 Percent on an Operational Basis • First-Quarter Global Net Revenues from the Immunology Portfolio Were $5.371 Billion, a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000016/0001551152-24-000016-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$12.310 Billion"},{"label":"EPS","value":"Diluted EPS of $0.77 on a GAAP Basis"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}